| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anna Bogusławska, Magdalena Godlewska, Alicja Hubalewska-Dydejczyk, Márta Korbonits, Jerzy Starzyk, Aleksandra Gilis-Januszewsk. Tall stature and gigantism in adult patients with acromegaly. European journal of endocrinology. 2024-02-23. PMID:38391173. |
the aim of this study was to evaluate the relationship between the height of adult patients with gh excess related to mid-parental height (mph) and population mean and to find whether taller patients with acromegaly come from tall families. |
2024-02-23 |
2024-02-25 |
Not clear |
| Vittoria Favero, Benedetta Zampetti, Emanuela I Carioni, Paolo Dalino Ciaramella, Erika Grossrubatscher, Daniela Dallabonzana, Iacopo Chiodini, Renato Cozz. Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study. Frontiers in endocrinology. vol 15. 2024-02-16. PMID:38362280. |
acromegaly is caused by excessive growth hormone (gh) and insulin-like growth factor 1 (igf1). |
2024-02-16 |
2024-02-18 |
Not clear |
| Fanny Chasseloup, Daniela Regazzo, Lucie Tosca, Alexis Proust, Emmanuelle Kuhn, Mirella Hage, Christel Jublanc, Karima Mokhtari, Mattia Dalle Nogare, Serena Avallone, Filippo Ceccato, Gerard Tachdjian, Sylvie Salenave, Jacques Young, Stephan Gaillard, Fabrice Parker, Anne-Laure Boch, Philippe Chanson, Jerome Bouligand, Gianluca Occhi, Peter Kamenick. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas. European journal of endocrinology. 2024-02-08. PMID:38330165. |
paradoxical increase of gh following oral glucose load has been described in ∼30% of patients with acromegaly and has been related to the ectopic expression of the glucose-dependent insulinotropic polypeptide (gip) receptor (gipr) in somatotropinomas. |
2024-02-08 |
2024-02-11 |
Not clear |
| D Costa, C Pellicano, V Mercuri, E D'Ascanio, G Buglione, G Cicolani, U Basile, G Leodori, P Gargiulo, E Rosat. Role of IL33 in chronic inflammation and microvascular damage as a reflection of organ damage on a cohort of patients with acromegaly. Journal of endocrinological investigation. 2024-02-08. PMID:38329608. |
acromegaly is a rare chronic disease, caused by the over-secretion of growth hormone (gh), that creates a pro-inflammatory state, but the exact mechanisms by which gh or insulin-like growth factor 1 (igf-1) act on inflammatory cells are not fully understood. |
2024-02-08 |
2024-02-10 |
Not clear |
| Rongrong Huang, Junyan Shi, Ruhan Wei, Jieli L. Challenges of insulin-like growth factor-1 testing. Critical reviews in clinical laboratory sciences. 2024-02-07. PMID:38323343. |
consequently, the measurement of igf-1 proves to be more specific and sensitive when diagnosing conditions such as acromegaly or gh deficiency. |
2024-02-07 |
2024-02-09 |
Not clear |
| Ichiro Nakazato, Kenichi Oyama, Hisashi Ishikawa, Yusuke Tabei, Chie Inomoto, Yoshiyuki Osamura, Akira Teramoto, Akira Matsun. Double pituitary neuroendocrine tumors in a patient with normal growth hormone level acromegaly: A case report and review of the literature. Surgical neurology international. vol 14. 2024-01-12. PMID:38213454. |
acromegaly is a rare disease caused by growth hormone (gh) hypersecretion caused by a pituitary neuroendocrine tumor (pitnet). |
2024-01-12 |
2024-01-14 |
Not clear |
| Ichiro Nakazato, Kenichi Oyama, Hisashi Ishikawa, Yusuke Tabei, Chie Inomoto, Yoshiyuki Osamura, Akira Teramoto, Akira Matsun. Double pituitary neuroendocrine tumors in a patient with normal growth hormone level acromegaly: A case report and review of the literature. Surgical neurology international. vol 14. 2024-01-12. PMID:38213454. |
however, some acromegaly patients show normal gh levels, and they can be a pitfall in clinical diagnosis. |
2024-01-12 |
2024-01-14 |
Not clear |
| Eline C Nijenhuis-Noort, Kirsten A Berk, Sebastian J C M M Neggers, Aart J van der Lel. The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin. Endocrinology and metabolism (Seoul, Korea). 2024-01-09. PMID:38192102. |
we will specifically address the interplay between gh, igf-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary. |
2024-01-09 |
2024-01-10 |
Not clear |
| E Vitali, A Grasso, M L Schiavone, G Trivellin, C Sobacchi, M Mione, G Mazziotti, A Lani. The direct impact of pegvisomant on osteoblast functions and bone development. Journal of endocrinological investigation. 2023-12-30. PMID:38159174. |
acromegaly is a chronic disease characterized by growth hormone (gh) hypersecretion, usually caused by a pituitary adenoma, resulting in elevated circulating levels of insulin-like growth factor type i (igf-i). |
2023-12-30 |
2024-01-05 |
Not clear |
| Nadia Sawicka-Gutaj, Aleksandra Derwich-Rudowicz, Aleksandra Biczysko, Solomiya Turchyn, Paulina Ziółkowska, Katarzyna Ziemnicka, Paweł Gut, Kacper Nijakowski, Marek Ruchał. Serum Phosphorus and Calcium as Biomarkers of Disease Status in Acromegaly. Biomedicines. vol 11. issue 12. 2023-12-23. PMID:38137499. |
acromegaly is a chronic disease caused by the hypersecretion of growth hormone (gh), leading to changes in the growth of visceral tissues and glucose impairment. |
2023-12-23 |
2023-12-25 |
Not clear |
| Peter Wolf, Luigi Maione, Peter Kamenický, Philippe Chanso. Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors. Archives of medical research. 2023-12-01. PMID:38040526. |
acromegaly is a chronic disease resulting from constantly elevated concentrations of growth hormone (gh) and insulin-like growth factor i (igf-i). |
2023-12-01 |
2023-12-10 |
Not clear |
| David R Clemmons, Martin Bidlingmaie. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly. Frontiers in endocrinology. vol 14. 2023-12-01. PMID:38027199. |
standard treatment for acromegaly focuses on the achievement of target absolute levels of growth hormone (gh) and insulin-like growth factor (igf-i). |
2023-12-01 |
2023-12-10 |
Not clear |
| David R Clemmons, Martin Bidlingmaie. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly. Frontiers in endocrinology. vol 14. 2023-12-01. PMID:38027199. |
measurement of both gh and igf-i remains an essential component of diagnosis and monitoring the effectiveness of treatment in acromegaly; however, treatment goals based only on previously identified absolute thresholds are not appropriate without taking into account the assay and reference ranges being employed. |
2023-12-01 |
2023-12-10 |
Not clear |
| Sophia Krombholz, Andreas Thomas, Philippe Delahaut, Martin Bidlingmaier, Katharina Schilbach, Geoffrey Miller, Mario Thevi. A combined top-down and bottom-up LC-HRMS/MS method for the quantification of human growth hormone in plasma and serum. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 72-73. 2023-11-23. PMID:37995539. |
the precise and accurate quantification of human growth hormone (gh) in plasma/ serum is crucial for the diagnosis and treatment of diseases like gh deficiency or acromegaly. |
2023-11-23 |
2023-11-29 |
human |
| Herman R, Janez A, Mikhailidis Dp, Poredos P, Blinc A, Sabovic M, Bajuk Studen K, Schernthaner Gh, Anagnostis P, Antignani Pl, Jensterle . Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency. Current vascular pharmacology. 2023-11-14. PMID:37962050. |
data on the prevalence of peripheral arterial disease in patients with acromegaly or growth hormone deficiency and the effects of gh and igf-1 levels on the disease progression is limited. |
2023-11-14 |
2023-11-20 |
Not clear |
| Keren-Sandyn García-de-la-Torre, Jacobo Kerbel, Amayrani Cano-Zaragoza, Moisés Mercad. Atypical Course of a Patient With AIP-Positive Acromegaly: From GH Excess to GH Deficiency and Back to GH Excess. JCEM case reports. vol 1. issue 2. 2023-11-01. PMID:37908467. |
atypical course of a patient with aip-positive acromegaly: from gh excess to gh deficiency and back to gh excess. |
2023-11-01 |
2023-11-08 |
Not clear |
| Keren-Sandyn García-de-la-Torre, Jacobo Kerbel, Amayrani Cano-Zaragoza, Moisés Mercad. Atypical Course of a Patient With AIP-Positive Acromegaly: From GH Excess to GH Deficiency and Back to GH Excess. JCEM case reports. vol 1. issue 2. 2023-11-01. PMID:37908467. |
we herein present the complex case of a patient with acromegaly due to a mammosomatotrope adenoma, with a germ-line aip (aryl hydrocarbon receptor-interacting protein) mutation, who had a chronic and protracted course of more than 15 years during which he was treated with surgery, somatostatin receptor ligands, dopamine agonist, and the gh receptor antagonist pegvisomant. |
2023-11-01 |
2023-11-08 |
Not clear |
| Caiyan Mo, Liyong Zhon. The effect of acromegaly on thyroid disease. Endocrine journal. 2023-10-25. PMID:37880078. |
long-term stimulation of thyroid follicular epithelium by high growth hormone (gh) and insulin-like growth factor-1 (igf-1) in patients with acromegaly can lead to thyroid dysfunction, goiter, thyroid nodules, and even thyroid cancer and thyroid-associated ophthalmopathy (tao). |
2023-10-25 |
2023-11-08 |
Not clear |
| Ansgar Heck, Kristin Godang, Tove Lekva, Kjersti Norman Markussen, Sara De Vincentis, Thor Ueland, Jens Bollersle. Endocortical Trabecularization in Acromegaly: The Cause for the Paradoxically Increased Vertebral Fracture Risk? JBMR plus. vol 7. issue 10. 2023-10-09. PMID:37808394. |
growth hormone (gh) is nonphysiologically increased in acromegaly, stimulating target tissues directly and indirectly via insulin-like growth factor type 1 (igf-1). |
2023-10-09 |
2023-10-15 |
Not clear |
| Ansgar Heck, Kristin Godang, Tove Lekva, Kjersti Norman Markussen, Sara De Vincentis, Thor Ueland, Jens Bollersle. Endocortical Trabecularization in Acromegaly: The Cause for the Paradoxically Increased Vertebral Fracture Risk? JBMR plus. vol 7. issue 10. 2023-10-09. PMID:37808394. |
despite gh having anabolic effects on bone growth and renewal, the risk of vertebral fractures is paradoxically increased in acromegaly. |
2023-10-09 |
2023-10-15 |
Not clear |